Drug Trial Radar · NCT07669454
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Oct 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Natureceuticals Sdn BhdIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic 300 capsule significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic 300 capsule safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 capsule vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic 300 capsule or placebo capsules (3 times per day) for 6 cycles of 20 days each (total \~120 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood samples assessment at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.
Conditions
- Fatigue Related to Cancer Treatment
- Colon Cancer
Interventions
Nuvastatic 300Drug
300mg capsule, (3 capsules X 3 times a day)
PlaceboDrug
300mg capsule, (3 capsules X 3 times a day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: From Screening to EOT (about 6 months)
- Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: From Screening to EOT (about 6 months)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Omega Hospital Chinna Gadhili
Visakhapatnam, Andhra Pradesh, India · Recruiting
K R Hospital
Mysore, Karnataka, India · Recruiting
Jeevanjyoti Cancer Hospital
Jalgaon, Maharashtra, India · Recruiting
Sangavi Multispeciality Hospital Pvt. Ltd,
Pune, Maharashtra, India · Recruiting
Erode Cancer Care Centre
Erode, Tamil Nadu, India · Recruiting
International Oncology Cancer Tower 1
Kanpur, Uttar Pradesh, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.